Galectin Therapeutics Inc. (NASDAQ:GALT) Major Shareholder James C. Czirr Sells 21,323 Shares

Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) major shareholder James C. Czirr sold 21,323 shares of the company's stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $3.06, for a total transaction of $65,248.38. Following the sale, the insider now directly owns 5,925,884 shares in the company, valued at approximately $18,133,205.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Galectin Therapeutics Stock Performance

NASDAQ:GALT traded up $0.21 on Thursday, hitting $3.50. The stock had a trading volume of 212,084 shares, compared to its average volume of 131,362. The stock has a market cap of $216.65 million, a P/E ratio of -4.73 and a beta of 0.84. Galectin Therapeutics Inc. has a 1 year low of $1.28 and a 1 year high of $4.27. The firm's fifty day simple moving average is $2.54 and its two-hundred day simple moving average is $2.10.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last issued its quarterly earnings results on Friday, March 29th. The company reported ($0.16) earnings per share (EPS) for the quarter. Equities research analysts predict that Galectin Therapeutics Inc. will post -0.66 EPS for the current year.

Wall Street Analysts Forecast Growth

GALT has been the topic of a number of analyst reports. HC Wainwright restated a "buy" rating and issued a $11.00 target price on shares of Galectin Therapeutics in a report on Tuesday, April 9th. StockNews.com upgraded shares of Galectin Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, April 1st.

Institutional Investors Weigh In On Galectin Therapeutics

Several large investors have recently modified their holdings of the stock. D.A. Davidson & CO. boosted its holdings in Galectin Therapeutics by 15.2% in the 3rd quarter. D.A. Davidson & CO. now owns 37,825 shares of the company's stock valued at $73,000 after purchasing an additional 5,000 shares during the period. Retirement Guys Formula LLC increased its position in shares of Galectin Therapeutics by 87.0% in the fourth quarter. Retirement Guys Formula LLC now owns 21,500 shares of the company's stock valued at $36,000 after acquiring an additional 10,000 shares during the period. Beacon Capital Management LLC boosted its stake in Galectin Therapeutics by 89.6% during the fourth quarter. Beacon Capital Management LLC now owns 23,905 shares of the company's stock worth $40,000 after acquiring an additional 11,300 shares in the last quarter. AE Wealth Management LLC boosted its stake in Galectin Therapeutics by 72.7% during the third quarter. AE Wealth Management LLC now owns 26,841 shares of the company's stock worth $52,000 after acquiring an additional 11,300 shares in the last quarter. Finally, Solutions 4 Wealth Ltd bought a new position in shares of Galectin Therapeutics in the fourth quarter worth approximately $60,000. Hedge funds and other institutional investors own 11.68% of the company's stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.